Everforth Inc quarterly report, Q1 FY2003

Business Context and Reporting Period

Company: On Assignment, Inc. (Note: Input metadata listed "Everforth Inc," but the filing text identifies the registrant as On Assignment, Inc.)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2003
Business Overview: A leading provider of skilled temporary professionals to clients in the science and healthcare industries. Operations are divided into two segments: Healthcare Staffing and Lab Support.

Key Financial Metrics

Metric Q1 2003 Q1 2002
Revenues $57,825,000 $42,111,000
Gross Profit $15,480,000 $13,545,000
Gross Margin 26.8% 32.2%
Operating Income (Loss) $(863,000) $4,210,000
Net Income (Loss) $(452,000) $2,869,000
EPS (Basic) $(0.02) $0.13
Cash and Equivalents $29,488,000 $95,256,000 (End of Q1 2002)
Working Capital $52,822,000 N/A
Total Debt None reported None reported

Material Changes vs. Prior Period

  • Revenue Growth: Revenues increased 37.3% to $57.8 million, driven primarily by the April 2002 acquisition of Health Personnel Options Corporation (HPO), which contributed $25.9 million in revenue. Excluding HPO, organic revenue decreased 24.3% due to weaker demand in the biotechnology sector and general economic conditions.
  • Profitability Decline: The company reported a net loss of $452,000 compared to a net income of $2.9 million in the prior year. Operating income turned negative ($863,000 loss) from a $4.2 million profit.
  • Margin Compression: Gross margin declined from 32.2% to 26.8%. The Healthcare Staffing segment's cost of services as a percentage of revenue increased to 77.3% (from 67.8%), largely due to the higher cost structure of the HPO acquisition.
  • Segment Performance:
    • Lab Support: Revenues decreased 16.9% to $24.5 million due to a 20.4% drop in temporary professionals on assignment and a 35.7% drop in conversion fees.
    • Healthcare Staffing: Revenues increased 64.3% to $33.3 million, but the segment reported an operating loss of $3.3 million compared to $1.2 million profit in 2002.
  • Cash Flow: Operating cash flow was negative $2.0 million, primarily due to working capital funding. Investing activities provided $3.0 million, including a $2.5 million recovery of HPO escrow funds.

Guidance, Outlook, and Risks

  • Restructuring Costs: The company incurred $413,000 in severance and office closure costs in March 2003 related to a lower-cost division within the Healthcare Staffing segment. These costs are included in SG&A expenses.
  • Seasonality: Management notes that demand typically declines from year-end through February, resulting in lower first-quarter results. The Lab Support segment also faces seasonal declines in Q2 and Q3.
  • Competition: Increased price competition in the nurse travel business from local start-ups is noted as a risk to margins and market share.
  • Capital Expenditures: The company is implementing a PeopleSoft enterprise-wide IT system. Approximately $4.3 million has been capitalized, with an additional $2 million to $3 million expected over the next nine months.
  • Stock Repurchases: The company repurchased 920,300 shares for $3.7 million during the quarter. 496,700 shares remain authorized for repurchase.
  • Goodwill Impairment Risk: While no impairment was recorded as of December 31, 2002, management noted that a permanent decline in market value could trigger a review of goodwill ($123.8 million) and indefinite-lived intangible assets.

Investor Verification Checklist

  • Organic Growth: Verify the sustainability of revenue growth excluding the HPO acquisition, given the 24.3% organic decline.
  • Margin Recovery: Assess the timeline for margin improvement in the Healthcare Staffing segment following the integration of HPO and recent cost-cutting measures.
  • Working Capital: Monitor the trend in accounts receivable, which increased by $4.7 million, and the associated cash burn in operating activities.
  • IT Implementation: Track the completion and cost overruns of the PeopleSoft system implementation.
  • Goodwill Valuation: Review future quarterly reports for any triggers related to goodwill impairment testing given the company's market value fluctuations.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.